Yaws Clinical Trial
Official title:
An Accessible Low-cost Plant Treatment for Cutaneous Ulcers
In a search for accessible treatment options, plant medicines used by different communities
in Papua New Guinea have been tested to identify the sap of the tree, Ficus septica, as a
promising antibacterial agent in vitro.
This is an open label clinical trial using an interventional approach, to compare the effect
of the antiseptic plant sap and standard topical antiseptic, on the rate of wound development
prevention and bacterial growth. If shown to be effective, this readily available plant
medicine can provide a zero-cost treatment option in remote areas of PNG.
The cutaneous ulcer is a painful and debilitating bacterial infection that is common in rural areas of Papua New Guinea (PNG). Systematic treatment with topical antiseptics such as chlorhexidine cream in theory represents a viable treatment option, but in reality, effective treatment of cutaneous ulcers in Papua New Guinea is greatly hindered by the remote and highly inaccessible areas that affected communities often live in. In a search for more accessible treatment options, plant medicines used by different communities in Papua New Guinea have been tested to identified the sap of the tree, Ficus septica, as a promising antibacterial agent in vitro. The sap displays comparable activity to chlorhexidine in disc diffusion assays with gram-positive bacterial wound pathogens. It also appears to dampen the pro-inflammatory responses of neutrophils by down regulating interleukin-6 expression. The sap forms a flexible plastic-like wound covering which may help deter flies from feeding on the wounds, and unlike chlorhexidine cream, the Ficus tree is easy to find where affected communities live. For this reason, this study aims to perform an open label clinical trial using an interventional approach, to compare the effect of this antiseptic plant sap and of a standard topical antiseptic, on the rate of wound development prevention and bacterial growth. If shown to be effective, this readily available plant medicine can provide a zero-cost treatment option in remote areas of PNG. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01382004 -
Single-dose Azithromycin for the Treatment of Yaws
|
Phase 3 | |
| Completed |
NCT03664063 -
PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )
|
Phase 2 | |
| Completed |
NCT03676140 -
Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )
|
Phase 3 | |
| Completed |
NCT01955252 -
Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea
|
Phase 3 | |
| Active, not recruiting |
NCT04753788 -
Evaluation of a LAMP Assay for T. Pallidum. Pertenue
|
||
| Active, not recruiting |
NCT05764876 -
Repurposing Clinically Approved Drugs for Yaws With an Insight Into the Cutaneous Ulcer Disease Syndrome (Trep-AByaws)
|
Phase 3 | |
| Completed |
NCT02344628 -
Comparison of Two Different Doses of Azithromycin for Treatment of Yaws
|
Phase 3 | |
| Completed |
NCT03683745 -
Integrated Mapping of Skin-presenting Neglected Tropical Diseases in Liberia
|
||
| Completed |
NCT02775617 -
Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
|
Phase 4 | |
| Completed |
NCT01841203 -
Dual Point-of-care Test for the Diagnosis of Yaws
|
N/A | |
| Completed |
NCT03490123 -
Evaluation of an Intensive 3-round MDA Strategy Towards Yaws Eradication
|
Phase 4 |